AstraZeneca PLC
12 December 2000
PART 2
AstraZeneca R&D Pipeline: NCEs
Cardiovascular
Compound Mechanism Indication Phase Estimated
Filing
MAA NDA
ZD4522 Statin Hyperlipidemia DFL 2Q 2Q
2001 2001
Melagatran Thrombin inhibitor Prevention of DFL 2H 2H
(s.c) VTE 2002* 2002*
H376/95 Thrombin inhibitor Prevention of DFL 2H 2H
(oral) VTE 2002* 2002*
H376/95 Thrombin inhibitor Prevention of DFL 2Q 2Q
(oral) stroke in AF 2003 2003
H376/95 Thrombin inhibitor Treatment of DFL 2003* 2003*
(oral) VTE
H376/95 Thrombin inhibitor Post MI CT >2003 >2003
(oral)
AR-C69931 P2T antagonist (iv) Arterial CT >2003 >2003
thrombosis
AZD 6140 (AR- P2T antagonist Arterial CT >2003 >2003
C126532) (oral) thrombosis
AZ 242 (AR- PPAR agonist Diabetes CT 2003 2003
H039242) /Insulin
resistance
AR-H049020 PPAR agonist Diabetes CT >2003 >2003
/Insulin
resistance
ZD4927 Factor Xa inhibitor Thrombosis CT >2003 >2003
AR-H050642 Atrial selective Atrial CT >2003 >2003
anti-arrhythmic fibrillation
(oral, incl. H345/52
for POC)
Nortran Atrial selective Atrial PC
inlicense anti-arrhythmic fibrillation
(oral)
* subject to confirmation
Gastrointestinal
AR-H047108 Reversible acid pump Acid related CT >2003 >2003
inhibitor GI disease
Reflux Inhibitor of Gastroesopha CT >2003 >2003
inhibitor transient lower -geal reflux
esophageal sphincter disease
relaxations (TLESR) (GERD)
Rofleponide Oral steroid with Inflammatory CT >2003 >2003
topical action bowel disease
H.pylori Nasal/oral Vaccine H.pylori PC
vaccine eradication
H.pylori NCE Oral treatment H.pylori PC
project eradication
CNS
NXY-059 Free radical Stroke CT 2003 2003
trapping agent
NAD299 5HT1A antagonist Anxiety CT >2003 >2003
/Depression
AR-A2 5HT1b antagonist Anxiety PC
/Depression
Remacemide NMDA antagonist Parkinson's CT >2003 >2003
Disease DFL 3Q 3Q
Huntington's 2001 2001
chorea
AR-R15896 NMDA antagonist CNS PC
disorders
AZD0947 K+ channel opener overactive CT >2003 >2003
bladder
AZD5106 NK-2 antagonist overactive PC
bladder
Oncology
Compound Mechanism Indication Phase Estimated
Filing
MAA NDA
Faslodex Anti-oestrogen 2nd line DFL 1Q 1Q
Advanced 2001 2001
breast cancer
Faslodex Anti-oestrogen 1st line DFL 1Q 1Q
Advanced 2002 2002
breast cancer
Iressa Signal transduction Solid tumours DFL 4Q 4Q
(ZD1839) inhibitor (Epidermal 2001 2001
growth factor
receptor tyrosine
kinase inhibitor)
ZD0473 3rd generation Solid tumours CT 2Q 2Q
platin (iv) 2003 2003
ZD0473 3rd generation Solid tumours PC
platin (oral)
ZD9331 Thymidilate synthase Solid tumours CT 2Q 2Q
inhibitor (iv) 2003 2003
ZD9331 Thymidilate synthase Solid tumours CT >2003 >2003
inhibitor (oral)
ZD6126 Vascular targeting Solid tumours PC
agent
AZD6474 Anti-angiogenic Solid tumours CT >2003 >2003
(Vascular
endothelial cell
growth factor
receptor tyrosine
kinase inhibitor)
AZD3409 Farnesyl-transferase Solid tumours CT >2003 >2003
inhibitor
( FAR )
Respiratory and Inflammation
Symbicort Inhaled Asthma DFL Launched TBD
Turbuhaler steroid/long-
acting b2 agonist
Symbicort Inhaled COPD DFL 3Q 2002 TBD
Turbuhaler steroid/long-
actin b2 agonist
Symbicort Inhaled Asthma/COPD DFL 3Q 2002 >2003
pMDI steroid/long-
acting b2 agonist
Viozan Dual dopamine/b2 COPD DFL 4Q 2001 4Q
agonist 2001
Rofleponide Intranasal steroid Rhinitis CT 2003 2003
palmitate
AR-C89855 Dual dopamine/b2 COPD CT >2003 >2003
agonist
ZD4407 5-lipoxygenase COPD CT >2003 >2003
inhibitor
ZD2315 Immuno modulator Rheumatoid CT >2003 >2003
Arthritis
CCR2b Immuno modulator Rheumatoid CT >2003 >2003
Arthritis
Pain Control
LEF Peripheral m- Acute CT 4Q 2002 4Q
agonist (iv) /chronic pain 2002
LTA Na channel blocker Analgesia CT 2003 2003
NO-naproxen Nitric oxide NSAID Acute CT >2003 >2003
derivative /chronic pain
NO-NSAID II Nitric oxide NSAID Acute PC
derivative /chronic pain
Delta agonist Delta opioid Acute PC
/chronic pain
Oral glycine NMDA Antagonist Neuropathic PC
pain
Infection
AZD2563 Oxazolidinone Gram positive CT >2003 >2003
antibiotic infections,
including
multi-
resistant
strains
AstraZeneca R&D Pipeline: Line Extensions
Cardiovascular
Compound Mechanism Indication Phase Estimated
Filing
MAA NDA
Seloken ZOK b-blocker CHF Appro- Appro-
/Toprol-XL ved ved
Atacand Angiotensin II Hypertension DFL 3Q 3Q
antagonist outcomes 2002 2002
(SCOPE study)
CHF outcomes DFL 2Q 2Q
(CHARM study) 2003 2003
Diabetic DFL >2003 >2003
retinopathy
Atacand Angiotensin II Hypertension Appro- Appro-
Plus antagonist ved ved
diuretic
NB. Paediatric programmes ongoing/planned : Zestril, Atacand,
Seloken/Toprol, Plendil
Gastrointestinal
Nexium Proton pump Multiple
inhibitor indications
(e.g. NSAID
and Dyspepsia)
Losec Proton pump
inhibitor
Entocort Oral steroid with Inflammatory Launched 4Q
topical action bowel disease 2000
CNS
Seroquel D2/5HT2 Granules DFL 2Q 2Q
antagonist 2001 2001
Seroquel D2/5HT2 Sustained DFL 3Q 3Q
antagonist release 2002 2002
Seroquel D2/5HT2 Mania DFL 2Q 3Q
antagonist 2003 2002
Zomig 5-HT1B/1D Rapimelt Launched Filed
receptor agonist
Zomig 5-HT1B/1D Adolescents DFL 2Q 2Q
receptor agonist 2002 2002
Zomig 5-HT1B/1D Nasal spray DFL Filed 1Q
receptor agonist 2001
Oncology
Arimidex Aromatase Adjuvant DFL 1Q 2002 1Q
inhibitor Breast Cancer 2002
Casodex Anti-androgen Early Prostate DFL 1Q 1Q
Cancer 2001* 2001*
Tomudex Thymidylate Other tumours CT/DFL 4Q 2001 -----
synthase
inhibitor
Zoladex LHRH agonist Premenopausal DFL Filed 1Q
Adjuvant 2001
Breast Cancer
* subject to confirmation
Respiratory
Accolate Leukotriene Paediatrics DFL Filed Launched
antagonist Asthma
Pulmicort Inhaled steroid Asthma DFL Launched Launched
Respules
Oxis Long-acting b2 COPD DFL 4Q >2003
agonist 2001
Oxis Long-acting b2 Asthma DFL Launched 2Q
agonist 2003
Oxis Long-acting b2 Paediatrics DFL 2Q 2Q
agonist Asthma 2001 2003
T3 Dry powder Asthma CT TBD TBD
inhaler, non-
reservoir
Pain Control
Compound Mechanism Indication Phase Estimated
Filing
MAA NDA
Naropin Sodium channel Spinal DFL 4Q 4Q
blocker anaesthesia 2001 2001
Intra- DFL 4Q 4Q
articular 2001 2001
admin.
Paediatrics DFL 4Q 4Q
2002 2002
Dental Gel Topical Dental DFL 1Q 1Q
anaesthesia anaesthesia 2002 2002
Infection
Merrem Carbapenem Hospital & DFL 4Q
antibiotic community 2000
acquired
pneumonia
Merrem Carbapenem Use in DFL 2Q
antibiotic Neutropenics 2003
Merrem Carbapenem Cystic DFL 4Q
antibiotic Fibrosis 2001
Merrem Carbapenem Skin and soft DFL 2Q
antibiotic tissue 2002
infections
Merrem Carbapenem Abdominal DFL 2Q
antibiotic infections 2002
AstraZeneca R&D Pipeline: Discontinued Compounds
Cardiovascular
Compound Mechanism
H409/22 NPY antagonist
CNS
Zendra GABAA enhancer
Infection
ME609 Antiviral
(Medivir joint
development)
Comments
AstraZeneca, Faslodex, Iressa, Symbicort, Turbuhaler, Viozan, Seloken ZOK,
Toprol-XL, Atacand, Nexium, Losec, Entocort, Seroquel, Zomig, Arimidex,
Casodex, Tomudex, Zoladex, Accolate, Pulmicort, Pulmicort Respules, Oxis,
Naropin, Merrem and Zendra are trade marks of the AstraZeneca group.
As disclosure of compound information is balanced by the
business need to maintain competitive advantage, some compound
information has not been disclosed at this time.
AstraZeneca is using a new terminology for the stage of
development;
PC - pre-clinical, prior to CD nomination
CT - concept testing, from CD nomination, through to phase I and
phase II completion
DFL - development for launch, phase IIIa and phase IIIb
activities conducted prior to filing
Other abbreviations;
TBD - to be decided
CD - Candidate Drug
MAA - Marketing Authorisation Application (Europe)
NDA - New Drug Application (USA)
12 December 2000
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.